title: Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells.
abstract: We show that the dual 5-α reductase enzyme inhibitor dutasteride prevents enhanced growth of both benign and malignant prostate cell lines, incubated with physiologic to supraphysiologic doses of testosterone. Using androgen-sensitive benign BPH-1 cells, LNCaP cancer cells, their derivative C4-2 cells, or Dunning rat cancer cells, we subjected 30,000 cells/well to concomitant treatment with 10(-9), 10(-8), or 10(-7) M testosterone in the presence of low (0.25 μM) or high (1.0 μM) doses of dutasteride. Both low- and high-dose dutasteride abrogated testosterone-stimulated growth of all 4 cell lines. If the in vitro data mimic conditions in men undergoing testosterone replacement, concomitant dutasteride use might make testosterone safe for men with benign prostatic hypertrophy, latent prostate cancer and perhaps even aggressive prostate cancer. Testosterone might also be used to prevent the rare anti-androgen side effects of dutasteride when used for benign prostatic hypertrophy and baldness. Further clinical investigation is indicated.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Alisky
authors.forename: Yaqiong
authors.initials: Y
authors.lastname: Tang
authors.forename: Gabriel K
authors.initials: GK
authors.lastname: Habermehl
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Iczkowski
references.citation: J Clin Endocrinol Metab. 2004 Aug;89(8):3821-9
references.pmid: 15292312
references.citation: J Urol. 2008 May;179(5):1736-40
references.pmid: 18343414
references.citation: Eur Urol. 2005 Nov;48(5):739-44
references.pmid: 16203079
references.citation: Prostate. 2006 Sep 1;66(12):1319-28
references.pmid: 16688747
references.citation: Prostate. 1999 Jan 1;38(1):46-54
references.pmid: 9973109
references.citation: Cancer Prev Res (Phila). 2009 Jun;2(6):518-24
references.pmid: 19491289
references.citation: Anticancer Res. 2005 May-Jun;25(3B):2075-83
references.pmid: 16158948
references.citation: ScientificWorldJournal. 2009 Jul 27;9:685-90
references.pmid: 19649507
references.citation: Ther Clin Risk Manag. 2009 Jun;5(3):427-48
references.pmid: 19707253
references.citation: Int J Cancer. 1994 May 1;57(3):406-12
references.pmid: 8169003